Host cellular immune response to pneumococcal lung infection in mice

A Kadioglu1, N A Gingles, K Grattan

  • 1Department of Microbiology & Immunology, University of Leicester, Leicester, United Kingdom.

Infection and Immunity
|January 20, 2000
PubMed

Insights

Pneumolysin, a key factor in pneumococcal pneumonia, significantly impacts lung inflammation and immune cell infiltration. Its absence alters bacterial growth and delays neutrophil and lymphocyte accumulation in the lungs.

Area of Science:

  • Microbiology
  • Immunology
  • Pathology

Background:

  • Pneumolysin is a critical virulence factor in Streptococcus pneumoniae infections.
  • Its precise role in modulating host inflammatory responses and cellular infiltration in the lungs remains incompletely understood.

Purpose of the Study:

  • To investigate the influence of pneumolysin production by Streptococcus pneumoniae on lung inflammation and cellular infiltration patterns.
  • To assess the impact of pneumolysin deficiency on bacterial growth dynamics within the lungs.

Main Methods:

  • Comparative analysis of lung inflammation and cellular infiltration in mice infected with wild-type and pneumolysin-deficient pneumococci.
  • Monitoring of bacterial growth kinetics and inflammatory cell accumulation over time post-infection.

Main Results:

  • Absence of pneumolysin led to a more rapid initial decline in bacterial numbers followed by slower growth.
  • Neutrophil infiltration into the lungs was delayed and less intense in infections with pneumolysin-deficient strains.
  • Lymphocyte accumulation occurred but was delayed in the absence of pneumolysin, without altering total lung lymphocyte counts.

Conclusions:

  • Pneumolysin significantly influences the timing and intensity of inflammatory cell recruitment, particularly neutrophils, during pneumococcal pneumonia.
  • The virulence factor plays a role in bacterial growth kinetics within the lung environment.
  • Understanding pneumolysin's immunomodulatory effects is crucial for developing targeted therapies against pneumococcal infections.

Related Concept Videos